Bernhard J Hering1, William R Clarke2, Nancy D Bridges3, Thomas L Eggerman4, Rodolfo Alejandro5, Melena D Bellin6, Kathryn Chaloner7, Christine W Czarniecki3, Julia S Goldstein3, Lawrence G Hunsicker7, Dixon B Kaufman8, Olle Korsgren9, Christian P Larsen10, Xunrong Luo11, James F Markmann12, Ali Naji13, Jose Oberholzer14, Andrew M Posselt15, Michael R Rickels13, Camillo Ricordi5, Mark A Robien3, Peter A Senior16, A M James Shapiro16, Peter G Stock15, Nicole A Turgeon10. 1. Schulze Diabetes Institute and Department of Surgery, University of Minnesota, Minneapolis, MN. 2. Clinical Trials Statistical and Data Management Center, University of Iowa, Iowa City, IA bhering@umn.edu. 3. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. 4. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. 5. Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL. 6. Schulze Diabetes Institute and Department of Pediatrics, University of Minnesota, Minneapolis, MN. 7. Clinical Trials Statistical and Data Management Center, University of Iowa, Iowa City, IA. 8. Division of Transplantation, Department of Surgery, University of Wisconsin, Madison, WI. 9. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. 10. Emory Transplant Center, Emory University, Atlanta, GA. 11. Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL. 12. Division of Transplant Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 13. Institute for Diabetes, Obesity and Metabolism and Departments of Surgery and Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 14. Division of Transplantation, University of Illinois Hospital and Health Sciences System, Chicago, IL. 15. Department of Surgery, University of California, San Francisco, San Francisco, CA. 16. Clinical Islet Transplant Program and Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Abstract
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50-80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS: The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50-80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized humanpancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified humanpancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS: The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
Authors: Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: A M James Shapiro; Camillo Ricordi; Bernhard J Hering; Hugh Auchincloss; Robert Lindblad; R Paul Robertson; Antonio Secchi; Mathias D Brendel; Thierry Berney; Daniel C Brennan; Enrico Cagliero; Rodolfo Alejandro; Edmond A Ryan; Barbara DiMercurio; Philippe Morel; Kenneth S Polonsky; Jo-Anna Reems; Reinhard G Bretzel; Federico Bertuzzi; Tatiana Froud; Raja Kandaswamy; David E R Sutherland; George Eisenbarth; Miriam Segal; Jutta Preiksaitis; Gregory S Korbutt; Franca B Barton; Lisa Viviano; Vicki Seyfert-Margolis; Jeffrey Bluestone; Jonathan R T Lakey Journal: N Engl J Med Date: 2006-09-28 Impact factor: 91.245
Authors: Richard M Bergenstal; David C Klonoff; Satish K Garg; Bruce W Bode; Melissa Meredith; Robert H Slover; Andrew J Ahmann; John B Welsh; Scott W Lee; Francine R Kaufman Journal: N Engl J Med Date: 2013-06-22 Impact factor: 91.245
Authors: A M Brooks; N Walker; A Aldibbiat; S Hughes; G Jones; J de Havilland; P Choudhary; G C Huang; N Parrott; N W A McGowan; J Casey; L Mumford; P Barker; K Burling; R Hovorka; M Walker; R M Smith; S Forbes; M K Rutter; S Amiel; M J Rosenthal; P Johnson; J A M Shaw Journal: Am J Transplant Date: 2013-10-01 Impact factor: 8.086
Authors: Rozalina G McCoy; Holly K Van Houten; Jeanette Y Ziegenfuss; Nilay D Shah; Robert A Wermers; Steven A Smith Journal: Diabetes Care Date: 2012-06-14 Impact factor: 19.112
Authors: Barbora Voglová; Martina Zahradnická; Peter Girman; Jan Kríž; Zuzana Berková; Tomáš Koblas; Ema Vávrová; Lenka Németová; Lucie Kosinová; David Habart; Eva Fábryová; Eva Dovolilová; Ivan Leontovyc; Tomáš Neškudla; Jan Peregrin; Jozef Kovác; Kvetoslav Lipár; Matej Kocík; Tomáš Marada; Jirí Svoboda; František Saudek Journal: Rev Diabet Stud Date: 2017-06-12
Authors: Peter Buchwald; Alejandro Tamayo-Garcia; Vita Manzoli; Alice A Tomei; Cherie L Stabler Journal: Biotechnol Bioeng Date: 2017-09-19 Impact factor: 4.530
Authors: Kristy Ou; Ming Yu; Nicholas G Moss; Yue J Wang; Amber W Wang; Son C Nguyen; Connie Jiang; Eseye Feleke; Vasumathi Kameswaran; Eric F Joyce; Ali Naji; Benjamin Glaser; Dana Avrahami; Klaus H Kaestner Journal: J Clin Invest Date: 2018-11-26 Impact factor: 14.808
Authors: Midhat H Abdulreda; Dora M Berman; Alexander Shishido; Christopher Martin; Maged Hossameldin; Ashley Tschiggfrie; Luis F Hernandez; Ana Hernandez; Camillo Ricordi; Jean-Marie Parel; Ewa Jankowska-Gan; William J Burlingham; Esdras A Arrieta-Quintero; Victor L Perez; Norma S Kenyon; Per-Olof Berggren Journal: Diabetologia Date: 2019-01-31 Impact factor: 10.122
Authors: Michael Skoumal; Kyle B Woodward; Hong Zhao; Feng Wang; Esma S Yolcu; Ryan M Pearson; Kevin R Hughes; Andrés J García; Lonnie D Shea; Haval Shirwan Journal: Biomaterials Date: 2018-11-13 Impact factor: 12.479